{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T17:42:14Z","timestamp":1743615734290},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jval.2015.05.005","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T09:56:48Z","timestamp":1437559008000},"page":"817-823","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort"],"prefix":"10.1016","volume":"18","author":[{"given":"Sameer","family":"Kotak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Mardekian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Horowicz-Mehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Gemmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.05.005_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/annrheumdis-2011-201066","article-title":"Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study","volume":"71","author":"Emery","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2015.05.005_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2015.05.005_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.61.7.630","article-title":"Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years","volume":"61","author":"Aleteha","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jval.2015.05.005_bib4","first-page":"964","volume":"69","author":"Smolen","year":"2010","journal-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis"},{"key":"10.1016\/j.jval.2015.05.005_bib5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/rheumatology\/kep242","article-title":"Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity","volume":"48","author":"Hyrich","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jval.2015.05.005_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.05.005_bib7","unstructured":"Rheumatoid arthritis: the management of rheumatoid arthritis in adults. Available from: http:\/\/www.nice.org.uk\/CG79fullguideline. [Accessed October 10, 2012]."},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2015.05.005_bib8","article-title":"British Society for Rheumatology Biologics Register","volume":"62","author":"Silman","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2015.05.005_bib9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2015.05.005_bib10","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s10198-007-0089-7","article-title":"The burden of rheumatoid arthritis and access to treatment: uptake of new therapies","volume":"8","author":"J\u00f6nsson","year":"2008","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2015.05.005_bib11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/rheumatology\/25.2.206","article-title":"Stanford Health Assessment Question Questionnaire modified to assess disability in British patients with rheumatoid arthritis","volume":"25","author":"Kirwan","year":"1986","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jval.2015.05.005_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","article-title":"A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries","volume":"40","author":"Curtis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jval.2015.05.005_bib13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2015.05.005_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R","article-title":"Multiple imputation of missing blood pressure covariates in survival analysis","volume":"18","author":"van Buuren","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2015.05.005_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti\u2013tumor necrosis factor agent to a second anti\u2013tumor necrosis factor agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2015.05.005_bib16","unstructured":"Rheumatoid arthritis: the management of rheumatoid arthritis in adults. Available from: http:\/\/www.nice.org.uk\/CG79fullguideline. [Accessed October 10, 2012]."}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515019683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515019683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:22:20Z","timestamp":1537456940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515019683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1098301515019683"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.05.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}